Medical news and careers, clearly connected
CareZelo
Manitoba
English
Menu

Public health updates

Due in 35 daysPublic healthCanada

Apotex reports manufacturing disruption causing shortage of fluoxetine 20 mg oral solution

Apotex reports its Apo-Fluoxetine (fluoxetine) 20 mg oral solution is in an actual shortage after a disruption in manufacturing. The actual shortage began Aug 18, 2026 and is estimated to end Dec 4, 2026.

Fluoxetine is a widely prescribed antidepressant — patients should not stop abruptly and should check stock and alternatives with their prescriber and pharmacy.

Shortage expected to end: Dec 4, 2026 All deadlines

Ask about this brief

Answers are written by AI from this brief and the original article it summarizes, and can be wrong. Check the original source before you act.

2 free questions a day without an account. Members ask as often as they like, free.

Not medical, legal or immigration advice.

Read the original

Official source: Apotex reports manufacturing disruption causing shortage of fluoxetine 20 mg oral solution (opens in a new tab) — Health Product Shortages Canada

Report a problem

Public healthCanada

Viokace shortage expected from Feb 2027 to Nov 2027 due to ingredient delays

Nestle Enterprises reports its Viokace (pancrelipase) tablet faces an anticipated shortage from Feb 1, 2027, after a shortage of an active ingredient delayed finished-drug production. The shortage is estimated to end Nov 30, 2027, with an allocation process effective Nov 1, 2026.

Pancrelipase is used by people with pancreatic insufficiency, including cystic fibrosis and chronic pancreatitis — patients and pharmacies should plan supply well ahead of the February start.

Official source: Health Product Shortages Canada (opens in a new tab)

Due todayPublic healthCanada

AbbVie to stop production of 40 mg Humira pens and syringes

AbbVie reports its Humira (adalimumab) 40 mg solution for subcutaneous injection, in pre-filled syringe and pen form, is to be discontinued on Oct 30, 2026, for business reasons.

Humira is a widely used biologic for arthritis, psoriasis and inflammatory bowel disease — patients and prescribers should confirm the switch to biosimilars or other alternatives.

Official source: Health Product Shortages Canada (opens in a new tab)

Due in 14 daysPublic healthCanada

Apotex reports manufacturing disruption causing shortage of 10 mg rupatadine tablets

Apotex reports its Apo-Rupatadine (rupatadine) 10 mg tablet is in an actual shortage after a disruption in manufacturing. The actual shortage began Oct 29, 2026 and is estimated to end Nov 13, 2026.

Rupatadine is a widely used antihistamine for allergies — patients and pharmacies should check stock and alternatives while the shortage runs.

Official source: Health Product Shortages Canada (opens in a new tab)